Camber Capital Management’s Sutro Biopharma STRO Stock Holding History

Camber Capital Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-60,000	Closed	-$6.03M	–	37
2020 Q3	$6.03M	Hold	60,000	–	–	0.32%	32
2020 Q2	$4.66M	Hold	60,000	–	–	0.27%	30
2020 Q1	$6.12M	Hold	60,000	–	–	0.37%	28
2019 Q4	$6.6M	Hold	60,000	–	–	0.34%	29
2019 Q3	$5.45M	Hold	60,000	–	–	0.29%	33
2019 Q2	$6.83M	Hold	60,000	–	–	0.32%	29
2019 Q1	$6.83M	Hold	60,000	–	–	0.34%	26
2018 Q4	$5.41M	Hold	60,000	–	–	0.26%	35
2018 Q3	$9M	Buy	+60,000	New	+$9.06M	0.39%	25

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Camber Capital Management's STRO Position: Q4 2020 in Review

Camber Capital Management sold out of Sutro Biopharma (STRO) in Q4 2020, closing a stake of 60,000 shares — an estimated $6.03M sold.

Camber Capital Management first reported a position in STRO in Q3 2018 and held it in 9 quarters. The position peaked at $9M in Q3 2018. 134 funds tracked by Wall St. Rank hold STRO as of Q4 2020.

Camber Capital Management reported no remaining Sutro Biopharma position as of Q4 2020 after selling out during the quarter.
Camber Capital Management sold 60,000 Sutro Biopharma shares in Q4 2020, an estimated $6.03M.
Camber Capital Management first reported a position in Sutro Biopharma in Q3 2018 and held it in 9 quarters.
Camber Capital Management's Sutro Biopharma position peaked at $9M in Q3 2018.
134 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2020.

Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.